MINI FUTURE LONG - ZEALAND PHARMA | Real-time Bid/Ask 08:14:47 2024-06-07 EDT | ||
| 6.15 EUR / 6.2 EUR | +2.24% |
|
| Current month | +2.37% | ||
| 1 month | +3.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 6.09 | +0.83% |
| 24-06-06 | 6.04 | +9.42% |
| 24-06-05 | 5.52 | -0.18% |
| 24-06-04 | 5.53 | -7.99% |
| 24-06-03 | 6.01 | +1.86% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 02:54 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB26CB |
| ISIN | DE000MB26CB7 |
| Date issued | 2023-01-10 |
| Strike | 198.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.61 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.05 € |
| Spread % | 0.81% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
651
DKK
Average target price
785.6
DKK
Spread / Average Target
+20.67%
- Stock Market
- Certificates
- Certificat
